# Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

> **NCT05986240** · PHASE1 · RECRUITING · sponsor: **Montefiore Medical Center** · enrollment: 38 (estimated)

## Conditions studied

- AML/MDS
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Danvatirsen
- **COMBINATION_PRODUCT:** Danvatirsen + Venetoclax

## Key facts

- **NCT ID:** NCT05986240
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-08
- **Primary completion:** 2027-06
- **Final completion:** 2030-03
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986240, "Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05986240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*